Every report comes from a Lived member, sent anonymously.
Have you tried Insulin pump therapy for Type 1 Diabetes?
Insulin pump therapy is a way of taking insulin through a small wearable device instead of several injections a day. Its medical name is continuous subcutaneous insulin infusion (CSII), which describes what it does: a steady flow of insulin into the fatty layer just under the skin. The pump holds rapid-acting insulin and releases it in two ways. A small, continuous background dose, called the basal rate, covers the body's needs between meals and overnight. Larger doses, called boluses, are given for meals or to bring down a high reading. Because the basal rate can be set to change through the day, a pump can follow patterns that a single daily long-acting injection cannot, such as lower needs during exercise. Most pumps now work together with a continuous glucose monitor (CGM), a small sensor worn on the skin that tracks glucose throughout the day. In these automated insulin delivery (AID) systems, sometimes called an artificial pancreas, software raises, lowers or pauses insulin about every five minutes based on where glucose is heading. The wearer still has to tell the system about meals.
Pumps are used mainly by people with type 1 diabetes, whose bodies no longer make insulin, and increasingly by people with type 2 diabetes who need insulin. The American Diabetes Association (ADA) now recommends an automated system as the preferred way to deliver insulin for people with type 1 diabetes, for adults and young people with type 2 diabetes who would otherwise take multiple daily injections, and for other forms of diabetes in which the body makes too little insulin. For people with type 2 diabetes who take only long-acting insulin and are not reaching their goals, an automated system may be worth considering. A pump can be started at diagnosis or years later, and it is used by children, teenagers, adults and older adults. What matters more than age is whether the person, or the caregiver of a young child or someone who needs help, can learn to run the system and handle problems. Pregnancy is a special case: most automated systems aim for glucose targets that were not designed for pregnancy, so decisions then are made with a specialist team.
Starting a pump involves a diabetes care team, often including a diabetes educator, who works out the settings with you: the basal rates, how much insulin covers a given amount of carbohydrate, and how far a correction dose lowers glucose. Training covers giving meal doses, changing the insertion site, responding to alarms and troubleshooting. The ADA treats this education as essential and expects it to be repeated as needed, not handed over once. There are two main designs. A tubed pump is worn on a belt or in a pocket and connects through thin tubing to a small flexible tube, or cannula, placed under the skin. A tubeless patch pump, often called a pod, sticks directly to the skin and is controlled from a handheld device or phone. With either design, the insertion site and supplies are changed every few days. Day to day, the wearer enters meals, keeps supplies on hand, responds to alarms and checks that insulin is actually flowing. Follow-up visits review the data the system records and adjust settings. Every pump user also needs a backup insulin plan, with pens or syringes and doses agreed in advance, for when the device fails or has to come off.
The first weeks involve a learning curve, with frequent contact with the care team while settings are adjusted. Automated systems tend to make the biggest difference overnight, when nobody is making manual adjustments. Glucose still varies, though. Illness, stress, hormones, exercise and meal estimates all affect results, and counting or estimating food remains part of daily life. Wearing a device around the clock takes adjustment. Alarms can interrupt sleep or work, adhesives can irritate skin, and some people dislike having a device on their body. Progress is usually tracked in two ways. A1C is a blood test that reflects average glucose over the past three months. With a CGM, time in range shows the share of the day glucose stays between 70 and 180 mg/dL, the standard target range in diabetes care, so more time in range means fewer highs and lows.
Compared with multiple daily injections, a standard pump without automation gives a modest benefit in type 1 diabetes. Pooled studies found A1C about 0.3 percentage points lower on average (for example, 7.7% instead of 8.0%), along with fewer episodes of severe low blood sugar in children, teenagers and adults. Many of these comparison studies were small and short. Automated systems show clearer gains. In the trials the US Food and Drug Administration (FDA) used to approve them, covering people aged 2 and older with type 1 diabetes and adults with type 2 diabetes, automated systems outperformed standard pumps, injections or usual care, with lower A1C and more time in range, and in type 1 diabetes, less time spent low. People who started with the highest A1C tended to improve the most. Large real-world studies, following users for longer than the trials did, have found similar results along with improvements in quality of life. Individual results vary, and the benefit depends on the system actually being worn and used.
The most important pump-specific risk is an interruption in insulin delivery. A pump uses only rapid-acting insulin, so if the cannula comes out, the tubing kinks or blocks, or the pump stops, there is no long-acting insulin working in the background. Glucose can climb and ketones, acids made when the body burns fat without enough insulin, can build up and lead to diabetic ketoacidosis (DKA). A high reading that does not come down as expected is a reason to check the site and tubing, test for ketones, follow the backup plan and contact the care team. Vomiting, trouble breathing, fruity-smelling breath or decreasing alertness are signs of DKA that need emergency care: call 911 or go to an emergency room. Low blood sugar remains possible, as with any insulin, so supplies for treating it should go wherever the pump goes. Insertion sites can become irritated or infected, and lumps can develop of thickened fatty tissue under the skin (lipohypertrophy); skin problems should be raised with the care team rather than tolerated. Cost and coverage are real barriers. Pumps, sensors and supplies are expensive, insurance rules vary, and losing coverage is one of the common reasons people stop. Others stop because the device is uncomfortable to wear, because of the mental load of managing it, or because results were not what they hoped. Returning to injections is a reasonable choice when a pump is not working for someone.
Last reviewed • Oct 2026
Educational content, not medical advice.
Share your experience with Insulin pump therapy, what's helped you, or ask the community a question.